
Index

A

AGT, *see* O⁶-Alkylguanine-DNA
alkyltransferase,

Alkylating drugs, *see also* DNA
interstrand crosslinks;

Nitrogen mustards,

O⁶-alkylguanine-DNA

alkyltransferase inhibition in
therapy potentiation, *see* O⁶-

Alkylguanine-DNA

alkyltransferase

DNA repair mechanisms,

overview, 74, 75, 77, 78, 143,
144

p53 linkage,

crosslink repair, 78–80

O⁶-methylguanine adduct
reversal, 80, 81

mismatch repair, 81–83),

overview, 77, 78

mechanism of action, 73, 74

monofunctional versus

bifunctional alkylating
agents, 75, 76

reactive oxygen species,

generation by genotoxic
agents, 84–86

p53-induced apoptosis role,

inactivation of p53, 97, 98

mitochondrial targeting of
p53, 95–97

nuclear import and export

regulation of p53, 92–95

overview, 86, 87

p53 regulation of redox

effector genes, 90–92

posttranslational

modification of p53,
87, 88

redox regulation of p53,
88–90

O⁶-Alkylguanine-DNA

alkyltransferase (AGT),

cancer prognosis value, 346

function, 144, 341

inhibitor use with alkylating
agents,

benzylated pyrimidines,
150, 151

O⁶-benzyl-2'-deoxyguanosine,
149, 150

O⁶-benzylguanine,

analogs, 150

clinical trials with BCNU,
151, 152

effect on alkylating agent
antitumor activity and
toxicity, 148, 149

enzyme resistance

possibilities, 152–154

mechanism of inhibition,
147, 148

nitrogen mustard

enhancement studies,
155–157

pharmacodynamics, 152

topoisomerase I inhibitor
enhancement studies,
157

O⁶-(4-bromophenyl)guanine, 149

O⁶-cycloalkenyl-guanines, 150

oligodeoxyribonucleotides

containing inhibitors, 151

- prospects, 157–159
 - rationale, 144
 - ribozymes, 147
 - phosphorylation in stress response, 127, 128
 - polymorphisms, 154
 - promoter methylation effects on chemotherapy resistance, 146, 147, 346
 - structure, 144
 - tumor activity and chemotherapy resistance, 145, 146
- Antioxidant supplements, DNA repair induction, 345, 346
- APE1, polymorphisms, 344
- Apoptosis, *see also* p53
- Bcl-2 control of apoptosis propensity in radiotherapy, 264, 265
 - signaling, 83, 84
- Artemis,
- hypomorphic mutations and B-cell lymphomas, 287, 288
 - V(D)J recombination role, 281–283
- AT, *see* Ataxia–telangiectasia,
- Ataxia–telangiectasia (AT),
- ATM functions, 305, 306
 - clinical features, 304
 - genomic instability, 304, 305
 - hypersensitivity to cytotoxic therapy, 306
- ATM, functions, 305, 306
- B**
- Base excision repair (BER),
- overview, 340
 - proteins,
 - DNA polymerase- β , 224
 - Hap1, 223, 224
 - Ogg1, 224
 - overview, 221, 222, 340
 - Xrcc1, 223
- Bcl-2, control of apoptosis propensity in radiotherapy,
- 264, 265
- O*⁶-Benzyl-2'-deoxyguanosine, *O*⁶-alkylguanine-DNA alkyltransferase inhibition, 149, 150
- O*⁶-Benzylguanine (BG),
- analogs, 150
 - clinical trials with BCNU, 151, 152
 - effect on alkylating agent antitumor activity and toxicity, 148, 149
 - enzyme resistance possibilities, 152–154
 - mechanism of *O*⁶-alkylguanine-DNA alkyltransferase inhibition, 147, 148
 - nitrogen mustard enhancement studies, 155–157
 - pharmacodynamics, 152
 - topoisomerase I inhibitor enhancement studies, 157
- BER, *see* Base excision repair
- BG, *see O*⁶-Benzylguanine
- Bleomycin,
- cell wall and plasma membrane effects, 177
 - combination therapy, 172
 - defense mechanisms against toxicity,
 - binding proteins, 178
 - cell wall and membrane barriers, 177, 178
 - DNA repair pathways, 179–182
 - hydrolase, 178, 179
 - DNA lesion induction and characteristics, 174–176
 - mechanism of action, 171, 172
 - metabolism, 172
 - RNA lesion induction and characteristics, 176, 177
 - structure, 171–174
 - toxicity, 172
 - tumor resistance, mechanisms, 173

- prospects for study, 187
- yeast studies,
 - advantages as model system, 182
 - hypersensitive mutants, 184
 - Imp2p in defense,
 - function, 185–187
 - hypersensitive mutants, 183, 185
 - structure, 185, 186
 - reverse genetics studies, 182, 183
- BLM, *see also* Bloom's syndrome,
 - functions, 307
 - phosphorylation in stress response, 128
- Bloom's syndrome (BS),
 - BLM mutations and functions, 307
 - clinical features, 306, 307
 - hypersensitivity to cytotoxic therapy, 306, 307
- BRCA1,
 - clinical implications in cancer, 299
 - DNA repair role,
 - DNA damage-induced phosphorylation, 327–329
 - DNA repair protein interactions, 326, 327
 - genomic stability maintenance, 330
 - homologous recombination, 329
 - nonhomologous end-joining, 329, 330
 - transcription-coupled repair, 330
 - gene structure and expression, 325
 - knockout mouse studies, 331, 332
 - mutation in breast cancer, 298, 324
 - protein–protein interactions, 310
 - structure and function, 298, 299
 - therapeutic implications, 332, 333
- BRCA2,
 - clinical implications in cancer, 299
 - DNA repair role,
 - DNA damage-induced phosphorylation, 327–329
 - DNA repair protein interactions, 326, 327
 - genomic stability maintenance, 330
 - homologous recombination, 329
 - nonhomologous end-joining, 329, 330
 - transcription-coupled repair, 330
 - gene structure and expression, 325
 - knockout mouse studies, 331, 332
 - mutation in breast cancer, 298, 324
 - structure and function, 298, 299
 - therapeutic implications, 332, 333
- O^6 -(4-Bromothienyl)guanine, 149, O^6 -alkylguanine-DNA alkyltransferase inhibition,
- BS, *see* Bloom's syndrome
- C**
- Carboplatin, toxicity, 2
- Cdc25,
 - p53 interactions and cell cycle regulation, 124, 125
 - therapeutic targeting, 133
- Cisplatin, *see also* DNA interstrand crosslinks,
 - cancer resistance, 2, 3
 - DNA adduct induction, 52
 - DNA repair mechanisms,
 - homologous recombination, 53–55
 - mismatch repair, 55, 56
 - nonhomologous end-joining mechanism, 55

- nucleotide excision repair, 53
 - overview, 52
 - efficacy, 51
 - history of use, 1
 - stress-activated protein kinase
 - activation, 118, 119
 - tumor cell sensitization,
 - cell cycle checkpoint
 - abrogation, 60–65
 - prospects, 65, 66
 - proteasome inhibitors, 59
 - pyrimidine nucleosides and
 - structures, 57–59
- D**
- DNA helicases, *see also* BLM; Bloom's syndrome; Rothmund–Thomson syndrome; Werner's syndrome; WRN,
 - DNA interstrand crosslinks (ICLs), *see also specific drugs*, drug types in induction, 31–33
 - repair,
 - chemotherapy agent design considerations, 43, 44
 - Fanconi anemia genes, 52
 - incision reactions, 34–36
 - mammalian cell modeling, 39–41
 - MUS308 role, 42, 43
 - nucleotide excision repair, 33, 34
 - recombination, 36–38
 - SNM1 role, 41, 42
 - translesion polymerases, 38, 39
 - DNA microarray, acquired chemoresistance studies, 4–6
 - DNA-PK,
 - inhibition in tumor cell sensitization to platinum drugs, 61, 62, 65
 - nonhomologous end-joining role, 225–227
 - V(D)J recombination relationship, 277, 278
 - DNA polymerase- β , base excision repair role, 224
- E**
- EGFR, *see* Epidermal growth factor receptor
 - Epidermal growth factor receptor (EGFR), tumor cell sensitization to platinum drugs, 63–65
 - EPO, *see Erythropoietin*
 - ErbB, mitogen-activated protein kinase activation links with growth factor receptors, DNA damage response, and drug resistance, 128, 129
 - Erythropoietin (EPO), oxygenation improvement of hypoxic tumors, 266
 - Extracellular regulated kinase, *see* Mitogen-activated protein kinases
- F**
- Fanconi anemia,
 - clinical features, 302, 303
 - genes,
 - DNA interstrand crosslink repair, 52
 - mutations and effects, 303
 - hypersensitivity to cytotoxic therapy, 303, 304
- G**
- Gadd45, p53 regulation and mitogen-activated protein kinase interactions, 123, 124
 - Gemcitabine, tumor cell sensitization to platinum drugs, 57
 - Genotype/phenotype relationship, DNA repair gene

- polymorphisms, 344, 345
- H**
- Hap1
base excision repair role, 223, 224
polymorphisms, cancer risks, and radiation therapy response prediction, 233, 238, 239
- HapMap, haplotype identification in human genome, 348
- Hepatocyte growth factor (HGF), mitogen-activated protein kinase activation links with growth factor receptors, DNA damage response, and drug resistance, 129, 130
- Hereditary nonpolyposis colorectal cancer (HNPCC),
clinical features, 299, 300
clinical implications of mismatch repair defects, 301, 302
gene mutations, 300, 301
Muir-Torre syndrome, 301
Turcot's syndrome, 301
- HGF, *see* Hepatocyte growth factor
- HNPCC, *see* Hereditary nonpolyposis colorectal cancer
- Homologous recombination,
BRCA1/2 role, 329
DNA crosslink repair, 19, 20
overview, 341, 342
platinum drug DNA damage repair, 53–55
proteins, 227, 228
- Hypoxia, *see* Radiotherapy
- I**
- ICLs, *see* DNA interstrand crosslinks
- Immunoglobulin genes, *see* V(D)J recombination
- Imp2p,
function, 185–187
hypersensitive yeast mutants, 183, 185
- structure, 185, 186
- J**
- JM-216, cancer resistance, 3
- Jun N-terminal kinase, *see* Mitogen-activated protein kinases
- L**
- Li-Fraumeni syndrome,
p53 mutations, 296, 297
radiosensitivity of cells, 297, 298
- LIG4, cancer prognosis value, 347
- M**
- MAPKs, *see* Mitogen-activated protein kinases
- Mechlorethamine, *see* Nitrogen mustards,
- MGMT, *see* O⁶-Alkylguanine-DNA alkyltransferase
- Mismatch repair (MMR),
disorders, *see* Hereditary nonpolyposis colorectal cancer
overview, 341
targeting in tumor cell sensitization to platinum drugs, 61
- Mitogen-activated protein kinases (MAPKs),
activation links with growth factor receptors, DNA damage response, and drug resistance,
ErbB, 128, 129
hepatocyte growth factor, 129, 130
apoptosis signaling, 84
DNA repair response mediation, 110, 111
extracellular regulated kinase pathway, 115–118
phosphatase therapeutic targeting, 132

stress-activated protein kinases,
 activators and inhibitors,
 111–113
 chemotherapy drug activation
 effects on cell survival,
 120, 121
 cisplatin activation, 118, 119
 DNA repair protein
 phosphorylation,
 O⁶-alkylguanine-DNA
 alkyltransferase, 127,
 128
 Blm helicase, 128
 nucleotide excision repair
 proteins, 126
 overview, 125
 p53-dependent repair
 proteins, 126, 127
 replication protein A, 127
 p38 pathway shared activators
 and inhibitors, 111, 114,
 115
 p53 interactions,
 Cdc25 and cell cycle
 regulation, 124, 125
 direct interactions, 122, 123
 Gadd45 regulation and
 kinase interactions,
 123, 124
 overview, 121, 122
 signaling integration via
 common pathways,
 119, 120
 stress response and DNA
 damage specificity, 118
 therapeutic targeting potential
 and limitations, 130–133
 tumor cell sensitization to
 platinum drugs, 62
 Mitomycin C, *see* DNA interstrand
 crosslinks
 MMR, *see* Mismatch repair
 MUS308, DNA interstrand crosslink
 repair role, 42, 43

N

NBS, *see* Nijmegen breakage
 syndrome
 NER, *see* Nucleotide excision repair
 NHEJ, *see* Nonhomologous end-
 joining
 Nijmegen breakage syndrome
 (NBS), features, 309
 Nitrogen mustards,
 O⁶-benzylguanine enhancement
 studies, 155–157
 cancer resistance,
 chronic lymphocytic leukemia,
 11–13
 epithelial cancer cell line
 studies, 13
 mechanisms, 10
 Xrcc-3/XPD overexpression
 studies, 21–23
 DNA alkylation, 74, 76
 DNA crosslinks, *see also* DNA
 interstrand crosslinks,
 induction and quantification, 10
 repair in cancer cells,
 DNA repair proteins, 13–15,
 23, 24, 74
 homologous
 recombinatorial repair,
 19, 20
 nonhomologous DNA end-
 joining, 17–19
 mechlorethamine history of use, 1
 Nonhomologous end-joining
 (NHEJ),
 BRCA1/2 role, 329, 330
 DNA crosslink repair, 17–19
 overview, 341, 342
 platinum drug DNA damage
 repair, 55
 polymorphisms, cancer risks, and
 radiation therapy response
 prediction, 237
 proteins,

- DNA-PK, 225–227
 - Ku proteins, 224, 226, 227
 - V(D)J recombination caretaker factors, 286, 287
 - NU1025, poly(ADP-ribose) polymerase inhibition, 202
 - Nucleotide excision repair (NER), DNA interstrand crosslink repair, 33, 34
 - overview, 341
 - phosphorylation of proteins, 126
 - platinum drug DNA damage repair, 53
 - proteins, 229, 230, 341
- O**
- Ogg1
 - base excision repair role, 224
 - polymorphisms, cancer risks, and radiation therapy response prediction, 233, 344, 345
 - Oxaliplatin,
 - cancer resistance, 3
 - DNA repair mechanisms,
 - homologous recombination, 53–55
 - mismatch repair, 55, 56
 - nonhomologous end-joining mechanism, 55
 - nucleotide excision repair, 53
 - overview, 52
 - toxicity, 2
 - tumor cell sensitization,
 - cell cycle checkpoint abrogation, 60–65
 - prospects, 65, 66
 - proteasome inhibitors, 59
 - pyrimidine nucleosides and structures, 57–59
- Oxidative stress, *see* Reactive oxygen species
- P**
- p53,
 - clinical implications in cancer, 298
 - disruption and tumor cell sensitization to platinum drugs, 60
 - DNA repair linkage with alkylating drugs, crosslink repair, 78–80
 - O⁶-methylguanine adduct reversal, 80, 81
 - mismatch repair, 81–83
 - overview, 77, 78
 - DNA repair role, 297
 - function, 297
 - Li-Fraumeni syndrome
 - mutations, 296, 297
 - mutation in cancer, 75, 258
 - phosphorylation, 121
 - reactive oxygen species and p53-induced apoptosis role with alkylating drugs, inactivation of p53, 97, 98
 - mitochondrial targeting of p53, 95–97
 - nuclear import and export regulation of p53, 92–95
 - overview, 86, 87
 - p53 regulation of redox effector genes, 90–92
 - posttranslational modification of p53, 87, 88
 - redox regulation of p53, 88–90
 - stress-activated protein kinase interactions,
 - Cdc25 and cell cycle regulation, 124, 125
 - direct interactions, 122, 123
 - Gadd45 regulation and kinase interactions, 123, 124
 - overview, 121, 122
 - PARP, *see* Poly(ADP-ribose) polymerase
 - PD128763, poly(ADP-ribose) polymerase inhibition, 201, 202

- PD0166285, radiosensitization of cells, 132
- Poly(ADP-ribose) polymerase (PARP),
functions, 198
induction by DNA damage, 197, 198
inhibitors,
 development, 201, 202, 204–206
 enzyme specificity, 202, 204
 NU1025, 202
 PD128763, 201, 202
 rationale for use with
 chemotherapy, 201, 202, 206
 structures, 203
isoforms and properties, 198–200
protein–protein interactions, 198, 199
radiation-induced apoptosis role, 263, 264
- Proteasome inhibitors, tumor cell sensitization to platinum drugs, 59
- Psoralens, *see also* DNA interstrand crosslinks,
- R**
- Radiotherapy,
 bioreductive drug targeting of hypoxic tumors, 267, 268
 clonogenic cell survival assay of radiosensitivity, 212
 DNA damage induction and features,
 base damage, 260
 DNA–protein crosslinking, 259, 260
 double-strand breaks, 261, 262
 single-strand breaks, 260, 261
 DNA repair,
 base damage repair studies, 216
 base excision repair proteins,
 DNA polymerase- β , 224
 Hap1, 223, 224
 Ogg1, 224
 overview, 221, 222
 Xrcc1, 223
 double-strand break rejoining studies,
 assays, 216, 217
 normal cells, 217, 218
 tumors, 218, 219
 exogenous DNA sequence damage and repair by host cells, 220, 221
 gene induction measurement, 230, 240
 homologous recombination proteins, 227, 228
 interindividual variability, 213, 214
 nonhomologous end-joining proteins,
 DNA-PK, 225–227
 Ku proteins, 224, 226, 227
 nuclear foci in double-stranded break repair, 228, 229
 nucleotide excision repair proteins, 229, 230
 overview of studies, 219, 220
 repair gene polymorphisms, cancer risks, and radiation therapy response prediction,
 Hap1, 233, 238, 239
 nonhomologous end-joining genes, 237
 Ogg1, 233
 overview, 230, 231
 XPG, 237
 Xrcc1, 231–235, 238, 239
 Xrcc3, 236, 234
 single-strand break rejoining studies,
 normal cells, 214–216
 tumors, 216

- geographic miss, 257, 258
 - normal tissue complication
 - probability, 211, 212
 - oxygenation improvement of
 - hypoxic tumors,
 - ARCON protocol, 266, 267
 - erythropoietin, 266
 - radiosensitizers, 267
 - rationale, 265, 266
 - PD0166285 radiosensitization of cells, 132
 - radiosensitivity determinants in mammalian cells,
 - Bcl-2 control of apoptosis propensity, 264, 265
 - damage extent, 262
 - oncogene-mediated radiation resistance, 262, 263
 - poly(ADP-ribose) polymerase role in radiation-induced apoptosis, 263, 264
 - thiols, 262
 - radiosensitivity genes, 213, 258, 259
 - treatment planning, 211, 212
 - tumor control probability, 211, 212
 - RAG genes, *see* V(D)J recombination
 - Reactive oxygen species (ROS),
 - apoptosis signaling, 83, 84
 - detoxification, 97, 98
 - generation by genotoxic agents, 84–86
 - p53-induced apoptosis role,
 - inactivation of p53, 97, 98
 - mitochondrial targeting of p53, 95–97
 - nuclear import and export regulation of p53, 92–95
 - overview, 86, 87
 - p53 regulation of redox effector genes, 90–92
 - posttranslational modification of p53, 87, 88
 - redox regulation of p53, 88–90
 - types, 83
 - Replication protein A (RPA),
 - phosphorylation in stress response, 127
 - ROS, *see* Reactive oxygen species
 - Rothmund–Thomson syndrome (RTS), features, 308, 309
 - RPA, *see* Replication protein A
 - RTS, *see* Rothmund–Thomson syndrome
- ## S
- SJG-136, mechanism of action, 43, 44
 - SNM1, DNA interstrand crosslink repair role, 41, 42
 - STI571, Abl inhibition, 132
 - Stress-activated protein kinases, *see* Mitogen-activated protein kinases
- ## T
- T-cell receptor genes, *see* V(D)J recombination
 - Tirapazamine (TPZ), targeting of hypoxic tumors, 267, 268
 - Topoisomerase I inhibitors, O⁶-benzylguanine enhancement studies, 157
 - TPZ, *see* Tirapazamine
- ## U
- UCN01, cell cycle checkpoint abrogation, 60, 61, 131
- ## V
- V(D)J recombination,
 - Artemis,
 - hypomorphic mutations and B-cell lymphomas, 287, 288
 - role, 281–283
 - DNA repair relationship, 277, 278
 - lymphoid malignancies and illegitimate recombination, 284, 285

non-homologous end-joining
factors as caretakers, 286,
287
overview, 273, 274
RAG gene defects,
animal models, 278, 279
human severe combined
immunodeficiency,
279–281
recombinase machinery, 275–277
structure and expression of
immunoglobulin and T-cell
receptor genes, 274, 275

W

Werner's syndrome,
clinical features, 308
WRN mutations and functions,
308
WRN, functions, 308

X


XPD,

cancer prognosis value, 346, 347
nitrogen mustard
chemoresistance role,
21–24
XPG, polymorphisms, cancer risks,
and radiation therapy response
prediction, 237
Xrcc1
base excision repair role, 223
cancer prognosis value, 347
polymorphisms, cancer risks, and
radiation therapy response
prediction, 231–235, 238,
239, 343, 344
Xrcc3
nitrogen mustard
chemoresistance role, 21–24
polymorphisms, cancer risks, and
radiation therapy response
prediction, 236, 234, 343, 345

Z

ZD0473, cancer resistance, 3

ABOUT THE EDITORS



Lawrence C. Panasci is Associate Director of the Oncology Centre for The Jewish General Hospital and Director of Medical Oncology at McGill University.

Dr. Panasci received his medical degree at Georgetown University and trained in medical oncology at Georgetown University and for a short time at the National Cancer Institute in Milan, Italy. He was an Assistant Professor at Upstate Medical Center in Syracuse University before joining the Faculty at McGill in 1980.

He is now a full Professor of Medicine. His research endeavors over the past two decades have focused on various topics in anti-cancer drug development.

Specifically he has developed a new anti-cancer agent which is in clinical trials. In addition, his laboratory has extensively examined the mechanism of DNA crosslinking agent drug resistance in both cell lines and clinical samples. The results of these investigations suggest that DNA repair plays a central role in the mechanism of DNA cross linking agent drug resistance.

Dr. Moulay Alaoui-Jamali is Professor of Experimental Oncology/Pharmacology at the Departments of Oncology and Medicine, Faculty of Medicine, McGill University. He received his PhD in Oncology in 1986 from the University of René Descartes and Sorbonne in Paris, followed by a postdoctoral training at the Cancer Center of the Roswell Park Memorial Institute in Buffalo, USA. His research career has included interdisciplinary studies spanning the fields of drug resistance in cancer, DNA repair vis-à-vis chemotherapy response, discovery of molecular switches for early cancer invasion, and novel therapeutics. He received several National and International awards, and served on many grant review panels, research forums, and boards. Dr. Alaoui-Jamali has authored more than 125 publications.

